YTN16 Syngeneic Model Service for Gastric Cancer

The YTN16 syngeneic model of gastric cancer grows a carcinogen-induced murine gastric adenocarcinoma in fully immunocompetent C57BL/6 hosts, combining FGFR4-driven growth with a richly documented metastatic and checkpoint-response profile. Alfa Cytology delivers the complete YTN16 workflow—authenticated cell banking, subcutaneous or gastric-wall implantation, burden-balanced randomization, scheduled dosing and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of YTN16 Syngeneic Model for Gastric Cancer

Until 2018, no mouse gastric cancer cell line could be transplanted into C57BL/6 mice—and the Yamamoto group’s report that year closed the gap. The team administered N-methyl-N-nitrosourea (MNU) in the drinking water of C57BL/6 mice and p53 heterozygous knockout littermates; a single tumor, arising in a p53-heterozygous animal, proved cultureable, grew as a subcutaneous transplant, and was subcloned into four lines—YTN2, YTN3, YTN5 and the most aggressive, YTN16. Molecular dissection revealed an actionable feature: YTN16 expresses fibroblast growth factor receptor 4 at 121-fold the level of its gentler sibling, and that addiction is causal—CRISPR-mediated FGFR4 knockout abolished subcutaneous tumorigenesis, while the selective inhibitor BLU9931 significantly suppressed tumor growth and peritoneal dissemination. The sibling lines proved equally instructive: YTN2 is spontaneously rejected in a CD8⁺ T-cell-dependent manner, making the YTN2/YTN16 pair a ready-made contrast between immunogenic and progressively growing gastric tumors.

Fig 1. Neoantigen mRNA vaccine efficacy in the YTN16-Luc peritoneal metastasis syngeneic model — treatment timeline (vaccine and anti-PD-1 on days 7, 14, 21), serial IVIS bioluminescence imaging, relative luciferase activity quantification at days 6/13/20/27, and terminal necropsy images showing peritoneal tumor burden reduction in the NeoAg-mRNA-LNP + anti-PD-1 group. (Nagaoka, Koji, et al., 2025)

Immunologically, YTN16 occupies a nuanced middle ground: anti-CTLA-4 eradicated tumors in four of five mice in a CD8⁺-dependent fashion, whereas anti-PD-1 slowed growth transiently without eradication, and anti-PD-L1 performed poorly in an independent profiling study—a resistance pattern linked to macrophage enrichment, exhausted T-cell states and alternative checkpoints such as EOMES, and one that combination therapy can break: adding anti-IL-17 to anti-PD-1 measurably increased neoantigen-specific CD8⁺ tumor-infiltrating T cells against the catalogued neoantigens mCdtl (H-2K^b-restricted) and mScarb2 and mZfp106 (H-2D^b-restricted). Its metastatic portfolio is broad—subcutaneous implants took in 8/8 mice with lung metastases in 7/8, lymph-node metastases in 3/8 and peritoneal dissemination in 5/5—and a highly metastatic subline, YTN16P, was selected by repeated intraperitoneal passage. Orthotopic injection into the gastric serosa recreates the organ context, and the model has even carried microbiome science: intratumoral or oral Streptococcus anginosus measurably accelerates YTN16 growth and reshapes its microenvironment. Caveats deserve note: kinetics are brisk, compressing dosing windows; the gastric-wall surgical format is technically demanding, with published warnings about cell leakage into the lumen or peritoneum; and the line is C57BL/6-restricted.

Cell Line Information: YTN16

Key characteristics of YTN16 and its documented derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, bioluminescence imaging and immune-profiling capabilities in-house, Alfa Cytology molds every YTN16 engagement around the sponsor’s hypothesis—selecting flank, orthotopic or peritoneal formats to match the metastatic question, calibrating dose and schedule to brisk kinetics, and pairing dosing with histology, MHC-dimer-based neoantigen analysis and flow cytometry for clean, decision-grade preclinical data.

Workflow of YTN16 Syngeneic Model Construction

Construction of the YTN16 syngeneic model is an implantation workflow whose quality rests on verified cells, vigorous C57BL/6 recipients, format-matched technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: YTN16 or luciferase-labeled stocks are cleared by mycoplasma PCR and identity verification, with FGFR4 expression documented as a molecular baseline; luciferase expression is titrated in vitro with D-luciferin before expansion.
2. Prepare recipients: C57BL/6 mice (typically 6–8 weeks old, males in most published designs) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (5 × 10⁶–8 × 10⁶ cells in 0.2 mL for flank implants; 5 × 10⁶ cells in 30 µL of 25% Matrigel for the orthotopic format; 1 × 10⁷ cells in 0.5 mL for intraperitoneal dissemination).
4. Implant: for the flank format, cells are injected subcutaneously with a fine needle at a fixed anatomical site; for the orthotopic format, a midline laparotomy under isoflurane exposes the stomach and cells are injected into the gastric serosal layer with care to avoid luminal or peritoneal leakage, followed by layered closure.
5. Randomize: when flank tumors reach palpability (typically within the first week), animals are assigned to groups balanced by tumor volume and body weight; orthotopic and peritoneal cohorts are randomized at implantation.
6. Dose and follow: test articles (checkpoint agents, FGFR4 inhibitors, cytokine blockade) are administered on schedule; flank tumors are measured with calipers two to three times weekly (volume typically 0.5 × length × width²), with bioluminescence substituted for labeled cohorts; body weight and clinical status are logged in parallel.
7. Terminate and analyze: tumors are resected and weighed; lungs, draining lymph nodes and peritoneal cavity are inspected for metastasis and scored histologically; tumor-infiltrating lymphocytes are analyzed by flow cytometry including MHC-dimer staining for the catalogued neoantigens, and tissues enter histopathology, immunohistochemistry and molecular analysis.

Fig 2. YTN16 Syngeneic Model construction workflow.

Case Study-YTN16 Syngeneic Model Development

Alfa Cytology maintains an active preclinical case-study file on the YTN16 platform: establishment-phase optimization of inoculum, format and randomization thresholds; in vivo growth tracking by caliper or bioluminescence; checkpoint, combination and FGFR4-targeted intervention studies; and systematic lymph-node, pulmonary and peritoneal metastasis quantification with matched neoantigen-specific and histological readouts. Representative growth curves, immune-profiling datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

YTN16 rewards teams that respect its brisk kinetics and its technically demanding orthotopic format—and that combination is where Alfa Cytology concentrates its effort:

• Format-flexible execution spanning flank, gastric-wall orthotopic and intraperitoneal dissemination designs.
• Authenticated YTN16 banks with documented FGFR4 expression baselines and luciferase options.
• A checkpoint-response dichotomy (CTLA-4-sensitive, PD-1/PD-L1-resistant) ideal for mechanism-driven combinations.
• MHC-dimer capability for tracking the catalogued mCdtl, mScarb2 and mZfp106 neoantigen responses.
• A YTN2/YTN16 comparison arm available for rejection-versus-progression contrasts.
• Dosing calendars engineered around brisk kinetics so compressed windows still deliver interpretable data.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the YTN16 syngeneic gastric cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.